Is PRLD or MLTX more profitable?

MoonLake Immunotherapeutics' return on equity of -85.15% beat Prelude Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Prelude Therapeutics N/A -118.24% -66.12% MoonLake Immunotherapeutics N/A -85.15% -60.52%

Is PRLD or AVBP more profitable?

ArriVent BioPharma's return on equity of -48.98% beat Prelude Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Prelude Therapeutics N/A -118.24% -66.12% ArriVent BioPharma N/A -48.98% -45.44%

Does the media favor PRLD or AVBP?

In the previous week, ArriVent BioPharma had 1 more articles in the media than Prelude Therapeutics. MarketBeat recorded 5 mentions for ArriVent BioPharma and 4 mentions for Prelude Therapeutics. ArriVent BioPharma's average media sentiment score of 1.26 beat Prelude Therapeutics' score of 0.65 indicating that ArriVent BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prelude Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ArriVent BioPharma 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer HROW or PRLD?

In the previous week, Prelude Therapeutics had 2 more articles in the media than Harrow. MarketBeat recorded 4 mentions for Prelude Therapeutics and 2 mentions for Harrow. Harrow's average media sentiment score of 1.17 beat Prelude Therapeutics' score of 0.65 indicating that Harrow is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prelude Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PRLD or AKTS more profitable?

Aktis Oncology's return on equity of 0.00% beat Prelude Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Prelude Therapeutics N/A -118.24% -66.12% Aktis Oncology N/A N/A N/A

Does the media prefer PRLD or AKTS?

In the previous week, Prelude Therapeutics and Prelude Therapeutics both had 4 articles in the media. Prelude Therapeutics' average media sentiment score of 0.65 beat Aktis Oncology's score of 0.54 indicating that Prelude Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prelude Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aktis Oncology 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PRLD or ARDX?

In the previous week, Ardelyx had 3 more articles in the media than Prelude Therapeutics. MarketBeat recorded 7 mentions for Ardelyx and 4 mentions for Prelude Therapeutics. Ardelyx's average media sentiment score of 0.74 beat Prelude Therapeutics' score of 0.65 indicating that Ardelyx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prelude Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ardelyx 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Prelude Therapeutics (PRLD) Competitors

$4.39 -0.21 (-4.57%)

Closing price 04:00 PM Eastern

Extended Trading

$4.48 +0.09 (+2.05%)

As of 04:20 PM Eastern

Compare

PRLD vs. MLTX, AVBP, HROW, AKTS, and ARDX

Should you buy Prelude Therapeutics stock or one of its competitors? MarketBeat compares Prelude Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Prelude Therapeutics include MoonLake Immunotherapeutics (MLTX), ArriVent BioPharma (AVBP), Harrow (HROW), Aktis Oncology (AKTS), and Ardelyx (ARDX).

How does Prelude Therapeutics compare to MoonLake Immunotherapeutics?

Prelude Therapeutics (NASDAQ:PRLD) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment.

Prelude Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market.

Prelude Therapeutics has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$16.72M	20.91	-$99.50M	-$1.00	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A

In the previous week, MoonLake Immunotherapeutics had 9 more articles in the media than Prelude Therapeutics. MarketBeat recorded 13 mentions for MoonLake Immunotherapeutics and 4 mentions for Prelude Therapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.89 beat Prelude Therapeutics' score of 0.65 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prelude Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MoonLake Immunotherapeutics	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Prelude Therapeutics presently has a consensus target price of $7.67, indicating a potential upside of 74.64%. MoonLake Immunotherapeutics has a consensus target price of $24.21, indicating a potential upside of 39.16%. Given Prelude Therapeutics' higher probable upside, equities analysts plainly believe Prelude Therapeutics is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41

79.7% of Prelude Therapeutics shares are owned by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 49.2% of Prelude Therapeutics shares are owned by company insiders. Comparatively, 10.4% of MoonLake Immunotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

MoonLake Immunotherapeutics' return on equity of -85.15% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-118.24%	-66.12%
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%

Summary

MoonLake Immunotherapeutics beats Prelude Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Prelude Therapeutics compare to ArriVent BioPharma?

Prelude Therapeutics (NASDAQ:PRLD) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

ArriVent BioPharma's return on equity of -48.98% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-118.24%	-66.12%
ArriVent BioPharma	N/A	-48.98%	-45.44%

79.7% of Prelude Therapeutics shares are owned by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are owned by institutional investors. 49.2% of Prelude Therapeutics shares are owned by company insiders. Comparatively, 8.6% of ArriVent BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Prelude Therapeutics has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$16.72M	20.91	-$99.50M	-$1.00	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

In the previous week, ArriVent BioPharma had 1 more articles in the media than Prelude Therapeutics. MarketBeat recorded 5 mentions for ArriVent BioPharma and 4 mentions for Prelude Therapeutics. ArriVent BioPharma's average media sentiment score of 1.26 beat Prelude Therapeutics' score of 0.65 indicating that ArriVent BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prelude Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ArriVent BioPharma	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Prelude Therapeutics presently has a consensus target price of $7.67, indicating a potential upside of 74.64%. ArriVent BioPharma has a consensus target price of $44.83, indicating a potential upside of 51.26%. Given Prelude Therapeutics' higher possible upside, equities research analysts plainly believe Prelude Therapeutics is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Prelude Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market.

Summary

ArriVent BioPharma beats Prelude Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Prelude Therapeutics compare to Harrow?

Harrow (NASDAQ:HROW) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

72.8% of Harrow shares are owned by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are owned by institutional investors. 12.8% of Harrow shares are owned by insiders. Comparatively, 49.2% of Prelude Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Harrow has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market. Comparatively, Prelude Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

Harrow has higher revenue and earnings than Prelude Therapeutics. Harrow is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$268.68M	5.42	-$5.14M	-$0.41	N/A
Prelude Therapeutics	$16.72M	20.91	-$99.50M	-$1.00	N/A

Harrow currently has a consensus target price of $69.43, suggesting a potential upside of 77.61%. Prelude Therapeutics has a consensus target price of $7.67, suggesting a potential upside of 74.64%. Given Harrow's stronger consensus rating and higher probable upside, research analysts clearly believe Harrow is more favorable than Prelude Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Prelude Therapeutics has a net margin of 0.00% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harrow	-5.57%	19.59%	2.26%
Prelude Therapeutics	N/A	-118.24%	-66.12%

In the previous week, Prelude Therapeutics had 2 more articles in the media than Harrow. MarketBeat recorded 4 mentions for Prelude Therapeutics and 2 mentions for Harrow. Harrow's average media sentiment score of 1.17 beat Prelude Therapeutics' score of 0.65 indicating that Harrow is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harrow	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prelude Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Harrow beats Prelude Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Prelude Therapeutics compare to Aktis Oncology?

Prelude Therapeutics (NASDAQ:PRLD) and Aktis Oncology (NASDAQ:AKTS) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Aktis Oncology has lower revenue, but higher earnings than Prelude Therapeutics. Aktis Oncology is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$16.72M	20.91	-$99.50M	-$1.00	N/A
Aktis Oncology	$8.28M	143.43	-$63.73M	-$0.38	N/A

Prelude Therapeutics presently has a consensus target price of $7.67, suggesting a potential upside of 74.64%. Aktis Oncology has a consensus target price of $34.60, suggesting a potential upside of 55.65%. Given Prelude Therapeutics' higher probable upside, research analysts clearly believe Prelude Therapeutics is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Aktis Oncology's return on equity of 0.00% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-118.24%	-66.12%
Aktis Oncology	N/A	N/A	N/A

In the previous week, Prelude Therapeutics and Prelude Therapeutics both had 4 articles in the media. Prelude Therapeutics' average media sentiment score of 0.65 beat Aktis Oncology's score of 0.54 indicating that Prelude Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prelude Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aktis Oncology	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

79.7% of Prelude Therapeutics shares are held by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are held by institutional investors. 49.2% of Prelude Therapeutics shares are held by insiders. Comparatively, 3.3% of Aktis Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Aktis Oncology beats Prelude Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Prelude Therapeutics compare to Ardelyx?

Prelude Therapeutics (NASDAQ:PRLD) and Ardelyx (NASDAQ:ARDX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends.

79.7% of Prelude Therapeutics shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 49.2% of Prelude Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Ardelyx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Ardelyx has higher revenue and earnings than Prelude Therapeutics. Ardelyx is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$16.72M	20.91	-$99.50M	-$1.00	N/A
Ardelyx	$407.32M	3.02	-$61.60M	-$0.23	N/A

Prelude Therapeutics currently has a consensus target price of $7.67, suggesting a potential upside of 74.64%. Ardelyx has a consensus target price of $15.73, suggesting a potential upside of 215.81%. Given Ardelyx's stronger consensus rating and higher possible upside, analysts clearly believe Ardelyx is more favorable than Prelude Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

Prelude Therapeutics has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Ardelyx's return on equity of -38.11% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-118.24%	-66.12%
Ardelyx	-13.58%	-38.11%	-11.85%

In the previous week, Ardelyx had 3 more articles in the media than Prelude Therapeutics. MarketBeat recorded 7 mentions for Ardelyx and 4 mentions for Prelude Therapeutics. Ardelyx's average media sentiment score of 0.74 beat Prelude Therapeutics' score of 0.65 indicating that Ardelyx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prelude Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ardelyx	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Prelude Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, Ardelyx has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market.

Summary

Ardelyx beats Prelude Therapeutics on 11 of the 17 factors compared between the two stocks.

Get Prelude Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRLD vs. The Competition

Export

Metric	Prelude Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$349.64M	$3.51B	$6.81B	$12.69B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-4.39	7.34	281.03	25.13
Price / Sales	20.91	1,215.58	574.87	80.86
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	4.03	16.89	11.03	6.21
Net Income	-$99.50M	-$12.54M	$3.48B	$347.60M
7 Day Performance	12.85%	-0.63%	0.54%	0.88%
1 Month Performance	-10.59%	-7.39%	-4.19%	-3.62%
1 Year Performance	430.00%	49.17%	63.11%	20.46%

Prelude Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRLD Prelude Therapeutics	2.0173 of 5 stars	$4.39 -4.6%	$7.67 +74.6%	+455.4%	$349.64M	$16.72M	N/A	120
MLTX MoonLake Immunotherapeutics	3.7427 of 5 stars	$19.22 -3.3%	$24.21 +26.0%	-65.2%	$1.41B	N/A	N/A	2	Upcoming Earnings
AVBP ArriVent BioPharma	2.5955 of 5 stars	$29.89 -0.9%	$44.83 +50.0%	+59.8%	$1.39B	N/A	N/A	40	News Coverage Upcoming Earnings
HROW Harrow	4.1866 of 5 stars	$36.95 -1.4%	$69.43 +87.9%	+24.1%	$1.38B	$268.68M	N/A	180	Upcoming Earnings
AKTS Aktis Oncology	2.2766 of 5 stars	$23.93 -1.2%	$34.60 +44.6%	N/A	$1.26B	$8.28M	N/A	76	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRLD) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prelude Therapeutics (PRLD) Competitors

PRLD vs. MLTX, AVBP, HROW, AKTS, and ARDX

How does Prelude Therapeutics compare to MoonLake Immunotherapeutics?

Summary

How does Prelude Therapeutics compare to ArriVent BioPharma?

Summary

How does Prelude Therapeutics compare to Harrow?

Summary

How does Prelude Therapeutics compare to Aktis Oncology?

Summary

How does Prelude Therapeutics compare to Ardelyx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRLD vs. The Competition

Prelude Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prelude Therapeutics (PRLD) Competitors

PRLD vs. MLTX, AVBP, HROW, AKTS, and ARDX

How does Prelude Therapeutics compare to MoonLake Immunotherapeutics?

Which has more risk & volatility, PRLD or MLTX?

Which has stronger earnings and valuation, PRLD or MLTX?

Does the media favor PRLD or MLTX?

Do analysts recommend PRLD or MLTX?

Do insiders and institutionals believe in PRLD or MLTX?

Is PRLD or MLTX more profitable?

Summary

How does Prelude Therapeutics compare to ArriVent BioPharma?

Is PRLD or AVBP more profitable?

Do insiders & institutionals have more ownership in PRLD or AVBP?

Which has higher valuation and earnings, PRLD or AVBP?

Does the media favor PRLD or AVBP?

Do analysts prefer PRLD or AVBP?

Which has more risk and volatility, PRLD or AVBP?

Summary

How does Prelude Therapeutics compare to Harrow?

Do insiders and institutionals hold more shares of HROW or PRLD?

Which has more volatility and risk, HROW or PRLD?

Which has stronger valuation & earnings, HROW or PRLD?

Do analysts prefer HROW or PRLD?

Is HROW or PRLD more profitable?

Does the media prefer HROW or PRLD?

Summary

How does Prelude Therapeutics compare to Aktis Oncology?

Which has better earnings & valuation, PRLD or AKTS?

Do analysts recommend PRLD or AKTS?

Is PRLD or AKTS more profitable?

Does the media prefer PRLD or AKTS?

Do insiders & institutionals hold more shares of PRLD or AKTS?

Summary

How does Prelude Therapeutics compare to Ardelyx?

Do institutionals & insiders hold more shares of PRLD or ARDX?

Which has higher valuation & earnings, PRLD or ARDX?

Do analysts prefer PRLD or ARDX?

Is PRLD or ARDX more profitable?

Does the media favor PRLD or ARDX?

Which has more volatility & risk, PRLD or ARDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRLD vs. The Competition

Prelude Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools